The Therapeutic Potential of Anti-HER2 2Rs15d Nanobody Labeled with 225Ac – an In Vitro and In Vivo Evaluation

Pruszyński, Marek; D’Huyvetter, Matthias; Rodak, Magdalena; Dekempeneer, Yana; Cędrowska, Edyta; Lahoutte, Tony; Bruchertseifer, Frank; Morgenstern, Alfred

doi:10.1016/j.jmir.2019.03.023

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies conjugated the nanobody with α-particles. For example, 225 Ac-2Rc15d in preclinical settings established its strong potential for targeted α-therapy 79,80 . While dosimetry calculations based on ex vivo biodistribution confirmed the predominant accumulation of [ 225 Ac]-2Rs15d in tumor and kidneys, the absorbed dose is considerably lower than for other HER2 radiopharmaceuticals 77,80 .…”

Section: Cd20 As a Targetmentioning

confidence: 99%

The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment

Martiniova¹,

Zieliński²,

Lin³

et al. 2022

Cancer J

View full text Add to dashboard Cite

Antibody-drug conjugates (ADCs) are designed to deliver cytotoxic payloads to distinctive target-expressing cancer cells. Following internalization, the ADCs are routed to different compartments in the cells, where cleavage of the linker causes release of the cytotoxic cargo. With such a delivery system, more effective payloads can reach cancer cells, allowing for more efficient treatment and dosing schedule. The monoclonal antibody (mAb) component of ADC plays a crucial role in the effective targeting of cancer cell-specific antigens while minimizing binding to normal cells. Often, the same mAbs used in ADCs can be labeled instead with radionuclides suitable for positron emission tomography or gamma-camera scintigraphy. To achieve high sensitivity and specificity for imaging, radiolabeled mAbs must have high affinity for the antigen, favorable pharmacokinetic properties, and a low toxicity profile. The use of radiolabeled mAbs permits the noninvasive interrogation of specific target expression on tumor cells and assessment of tumor heterogeneity in vivo by a simple diagnostic imaging scan that may include the whole body in the field of view. With this approach, radiolabeled mAbs can serve as important imaging biomarkers to predict the optimal delivery of ADCs to tumors and be used to monitor therapy with follow-up scans. Moreover, the same mAb can then be radiolabeled with an analogous radionuclide for the delivery of β-emitters, α-particles, or Auger electrons as part of a radioimmunotherapy approach. The purpose of this review is to introduce key concepts regarding radiolabeled mAbs targeting various tumor antigens (CD20, CDH3, type I insulinlike growth factor receptor, prostate-specific membrane antigen, and human epidermal growth factor receptor 2) that are being used in the clinical setting or undergoing development.

show abstract

Section: Cd20 As a Targetmentioning

confidence: 99%